KNOTUS Co.Ltd
HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug deve… Read more
KNOTUS Co.Ltd (278650) - Net Assets
Latest net assets as of September 2025: ₩112.17 Billion KRW
Based on the latest financial reports, KNOTUS Co.Ltd (278650) has net assets worth ₩112.17 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩156.41 Billion) and total liabilities (₩44.24 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩112.17 Billion |
| % of Total Assets | 71.72% |
| Annual Growth Rate | 38.31% |
| 5-Year Change | 108.55% |
| 10-Year Change | N/A |
| Growth Volatility | 34.06 |
KNOTUS Co.Ltd - Net Assets Trend (2016–2024)
This chart illustrates how KNOTUS Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for KNOTUS Co.Ltd (2016–2024)
The table below shows the annual net assets of KNOTUS Co.Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩111.87 Billion | +8.01% |
| 2023-12-31 | ₩103.57 Billion | +47.38% |
| 2022-12-31 | ₩70.28 Billion | +8.81% |
| 2021-12-31 | ₩64.59 Billion | +20.40% |
| 2020-12-31 | ₩53.64 Billion | +28.14% |
| 2019-12-31 | ₩41.86 Billion | +102.54% |
| 2018-12-31 | ₩20.67 Billion | +28.84% |
| 2017-12-31 | ₩16.04 Billion | +92.00% |
| 2016-12-31 | ₩8.36 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to KNOTUS Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 321.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩23.26 Billion | 20.80% |
| Common Stock | ₩8.67 Billion | 7.75% |
| Other Components | ₩79.94 Billion | 71.45% |
| Total Equity | ₩111.87 Billion | 100.00% |
KNOTUS Co.Ltd Competitors by Market Cap
The table below lists competitors of KNOTUS Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Industrial Urban Development Group Limited
PINK:SIUDF
|
$56.67 Million |
|
Value Grupo Financiero S.A.B. de C.V
MX:VALUEGFO
|
$56.69 Million |
|
Chegg Inc
NYSE:CHGG
|
$56.69 Million |
|
EKTER S.A. NA EO 052
F:J97
|
$56.71 Million |
|
Cat Loi JSC
VN:CLC
|
$56.64 Million |
|
Solitario Exploration & Royalty Corp
NYSE MKT:XPL
|
$56.63 Million |
|
CMBC CAP.HLD.(NEW) -40
F:4C30
|
$56.63 Million |
|
Sanitar Co Ltd
TW:1817
|
$56.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in KNOTUS Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 101,590,276,710 to 111,874,278,310, a change of 10,284,001,600 (10.1%).
- Net loss of 8,564,408,980 reduced equity.
- Share repurchases of 3,115,436,160 reduced equity.
- New share issuances of 2,794,147,000 increased equity.
- Other factors increased equity by 19,169,699,740.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-8.56 Billion | -7.66% |
| Share Repurchases | ₩3.12 Billion | -2.78% |
| Share Issuances | ₩2.79 Billion | +2.5% |
| Other Changes | ₩19.17 Billion | +17.14% |
| Total Change | ₩- | 10.12% |
Book Value vs Market Value Analysis
This analysis compares KNOTUS Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.95x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 6.76x to 0.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩185.67 | ₩1256.00 | x |
| 2017-12-31 | ₩294.37 | ₩1256.00 | x |
| 2018-12-31 | ₩372.50 | ₩1256.00 | x |
| 2019-12-31 | ₩635.71 | ₩1256.00 | x |
| 2020-12-31 | ₩789.69 | ₩1256.00 | x |
| 2021-12-31 | ₩915.74 | ₩1256.00 | x |
| 2022-12-31 | ₩996.42 | ₩1256.00 | x |
| 2023-12-31 | ₩1265.09 | ₩1256.00 | x |
| 2024-12-31 | ₩1328.74 | ₩1256.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently KNOTUS Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.72%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.50x
- Recent ROE (-7.66%) is below the historical average (11.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 29.14% | 21.82% | 0.57x | 2.34x | ₩1.60 Billion |
| 2017 | 26.89% | 14.70% | 0.90x | 2.04x | ₩2.71 Billion |
| 2018 | 17.20% | 9.55% | 0.85x | 2.12x | ₩1.49 Billion |
| 2019 | 10.02% | 9.11% | 0.75x | 1.47x | ₩8.87 Million |
| 2020 | 15.48% | 14.19% | 0.79x | 1.38x | ₩2.94 Billion |
| 2021 | 17.08% | 17.13% | 0.68x | 1.47x | ₩4.57 Billion |
| 2022 | -4.26% | -3.47% | 0.50x | 2.45x | ₩-10.02 Billion |
| 2023 | -0.16% | -0.31% | 0.31x | 1.69x | ₩-10.32 Billion |
| 2024 | -7.66% | -14.72% | 0.35x | 1.50x | ₩-19.75 Billion |
Industry Comparison
This section compares KNOTUS Co.Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $259,224,420,269
- Average return on equity (ROE) among peers: -0.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| KNOTUS Co.Ltd (278650) | ₩112.17 Billion | 29.14% | 0.39x | $56.64 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.37 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $229.70 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $409.02 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $453.92 Million |
| GeneOne Life Science Inc (011000) | $23.71 Billion | -35.27% | 0.34x | $52.94 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $14.76 Million |
| Seoulin Bioscience Co.Ltd (038070) | $59.92 Billion | 8.17% | 0.31x | $27.84 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $964.67 Million |
| iNtRON Biotechnology Inc (048530) | $49.15 Billion | -1.24% | 0.21x | $83.99 Million |
| Synergy Innovation Co. Ltd (048870) | $71.09 Billion | 0.00% | 0.77x | $77.78 Million |